Table 2 Comparison of treatment tolerance and outcomes between the DM and non-DM groups.
From: Impact of Diabetes Mellitus on Head and Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy
Variables | Adjuvant CCRT (n = 130) | Primary CCRT (n = 426) | ||||
|---|---|---|---|---|---|---|
DM n = 25 | Non-DM n = 105 | p value | DM n = 59 | Non-DM n = 367 | p value | |
Highest dose of RT received (mean ± SD), Gy | 6272.00 ± 612.35 | 6196.00 ± 965.28 | 0.71 | 6907.59 ± 863.05 | 7043.44 ± 640.54 | 0.25 |
Number of RT treatment received with the highest radiation dose (mean ± SD) | 32.70 ± 2.45 | 31.96 ± 3.53 | 0.38 | 34.66 ± 5.58 | 35.27 ± 2.68 | 0.56 |
Length of RT treatment (mean ± SD), weeks | 7.51 ± 1.95 | 6.83 ± 1.32 | 0.065 | 7.42 ± 1.22 | 7.59 ± 1.29 | 0.51 |
CT CDDP dose (mean ± SD), mg/m2 | 175.30 ± 84.03 | 214.88 ± 68.25 | 0.014 | 142.84 ± 79.49 | 187.83 ± 76.19 | <0.001 |
Weight loss during CCRT (mean ± SD), % | −6.48 ± 8.99 | −3.33 ± 10.04 | 0.14† | −6.17 ± 9.27 | −4.49 ± 6.84 | 0.078† |
Neutropenic fever | 20.0% | 9.5% | 0.26 | 11.9% | 8.4% | 0.39 |
Infection | 52.0% | 30.5% | 0.042 | 45.8% | 22.9% | <0.001 |
Grade ≥3 mucositis | 28.0% | 41.0% | 0.45 | 27.1% | 47.7% | 0.009 |
Grade ≥3 pharyngitis | 20.0% | 20.0% | 0.94 | 35.6% | 49.3% | 0.14 |
Grade ≥3 dermatitis | 5.0% | 7.1% | 0.79 | 10.3% | 12.8% | 0.87 |
Grade ≥3 xerostomia | 0.0% | 1.2% | 0.60 | 3.4% | 1.2% | 0.34 |
Grade ≥3 hematological toxicity* | 47.6% | 33.3% | 0.22 | 65.7% | 39.3% | 0.004 |
Treatment-related death | 8.0% | 3.8% | 0.71 | 10.2% | 3.5% | 0.051 |
1-year RFS rate | 64.0% | 67.6% | 0.73 | 53.4% | 66.4% | 0.055 |
2-year RFS rate | 48.0% | 52.4% | 0.69 | 46.6% | 50.3% | 0.60 |
1-year OS rate | 80.0% | 74.3% | 0.55 | 60.3% | 77.0% | 0.007 |
2-year OS rate | 52.0% | 53.3% | 0.90 | 48.3% | 57.7% | 0.18 |
